Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.
about
Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsClinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events.Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.
P2860
Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Progression-free survival as a ...... l in metastatic breast cancer.
@ast
Progression-free survival as a ...... l in metastatic breast cancer.
@en
type
label
Progression-free survival as a ...... l in metastatic breast cancer.
@ast
Progression-free survival as a ...... l in metastatic breast cancer.
@en
prefLabel
Progression-free survival as a ...... l in metastatic breast cancer.
@ast
Progression-free survival as a ...... l in metastatic breast cancer.
@en
P2093
P2860
P356
P1476
Progression-free survival as a ...... l in metastatic breast cancer.
@en
P2093
Catherine Beauchemin
Dan Cooper
Jean Lachaine
Louise Yelle
Marie-Ève Lapierre
P2860
P304
P356
10.2147/OTT.S63302
P407
P577
2014-06-18T00:00:00Z